Expanded Collaboration Enhances Women's Healthcare Access
Aspira Women’s Health Inc. (“Aspira”) (NASDAQ: AWH), a pioneering company in bio-analytical women’s health diagnostics, is excited to announce its expanded collaboration with BioReference Health, LLC. This partnership builds on their previous efforts to support women’s health providers and advances the mission of improving healthcare accessibility and outcomes for women.
Introducing OvaWatch: A Key Component of OvaSuite
Under this newly enhanced agreement, Aspira and BioReference will jointly market the comprehensive OvaSuite portfolio, which includes OvaWatch and Ova1Plus, specifically to women’s healthcare provider clients associated with BioReference. Since 2022, the two companies have been successfully co-marketing and distributing Ova1Plus, and the recent approval of OvaWatch has opened up new opportunities for the partnership. This approval allows OvaWatch to be offered to millions of women in surrounding states.
OvaWatch’s Significant Impact
OvaWatch is recognized as the only non-invasive blood test for assessing the risk of ovarian cancer in patients with indeterminate or benign adnexal masses. It boasts a remarkable 99% negative predictive value, enabling healthcare providers to monitor and tailor treatment options effectively. This innovation paves the way for improved patient outcomes and highlights Aspira's commitment to advancing women’s health diagnostics.
Enthusiasm from Leadership
Nicole Sandford, CEO of Aspira, expressed her excitement about this collaboration, pointing out the shared vision with BioReference to enhance women's healthcare. She emphasized that their combined efforts will help in the swift adoption of OvaWatch without incurring additional costs to the healthcare providers, thereby facilitating patients' access to essential diagnostics.
Additionally, Ellen Beausang, Chief Commercial Officer of BioReference, reinforced the importance of this partnership. The addition of OvaWatch aligns with BioReference Health's commitment to providing high-quality testing options that assist women’s healthcare professionals in improving patient care and health outcomes.
About BioReference Health
BioReference Health, LLC stands out in the diagnostic testing landscape by prioritizing exceptional service and cutting-edge solutions. Based in New Jersey, the company is integrated with many of the largest health plans in the United States and processed over 9 million tests in the preceding year. BioReference offers a diverse range of tests and supports medical practices, hospitals, correctional institutions, and governmental organizations with tailored solutions and extensive health screening programs.
Understanding the OvaSuite Portfolio
The OvaSuite portfolio includes advanced solutions that aid in the detection of ovarian cancer among the over 1.2 million American women diagnosed with adnexal masses annually. The suite combines the innovative OvaWatch and Ova1Plus, offering a robust diagnostic approach for those in need.
Future Developments in Diagnostics
Aspira is also diligently developing additional tests aimed at expanding its ovarian cancer portfolio and addressing the significant need for non-invasive diagnostics in endometriosis. The company's innovative approach involves the use of microRNA and protein biomarkers to enhance current tests' sensitivity and specificity. Aspira is dedicated to changing the landscape of gynecologic disease diagnostics with continuous advancements.
Frequently Asked Questions
What is the purpose of the collaboration between Aspira and BioReference?
The collaboration aims to enhance the marketing and distribution of the OvaSuite portfolio, particularly OvaWatch, to improve women's health diagnostics.
What is OvaWatch?
OvaWatch is a non-invasive blood test that assesses the risk of ovarian cancer in patients with indeterminate or benign adnexal masses.
What are the advantages of using OvaWatch?
OvaWatch offers a 99% negative predictive value, which helps healthcare providers make informed decisions regarding patient monitoring and treatment.
Who will benefit from the expanded collaboration?
The partnership primarily benefits women’s healthcare providers and their patients in New York and New Jersey who will gain access to OvaWatch diagnostic tools.
What are Aspira's future plans for diagnostics?
Aspira is focused on developing additional tests for ovarian cancer and endometriosis, utilizing advanced biomarkers to enhance non-invasive diagnostic capabilities.
